Kangpu Pharmaceuticals

Kangpu Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology, immunology, and inflammation. The company leverages its proprietary X-Synergy and molecular glue technology platforms to develop a robust pipeline of protein degraders targeting previously undruggable proteins. Its lead candidates, including KPU-044 and KPU-052, are currently undergoing clinical trials for hematologic malignancies and autoimmune diseases like systemic lupus erythematosus. Kangpu is headquartered in Shanghai with additional operations in Suzhou and the United States. The company is backed by prominent investors such as Legend Capital and IDG Capital.